Progression-free survival was significantly longer for those patients treated with bevacizumab plus chemotherapy than for those with chemotherapy alone ( median : 63 months [ 95 % CI 54-72 ] vs 42 months [ 39-47 ] , respectively , stratified hazard ratio [ HR ] 075 [ 95 % CI 061-093 ] , two-sided stratified log-rank p = 00068 ) .